Organovo Stock Forecast, Price & News

Wall Street analysts have given Organovo a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Organovo wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Organovo is scheduled to release its next quarterly earnings announcement on Monday, March 1st 2021.
View our earnings forecast for Organovo.

Organovo Holdings, Inc. (NASDAQ:ONVO) issued its quarterly earnings data on Thursday, August, 8th. The medical research company reported ($1.00) earnings per share (EPS) for the quarter, meeting the Thomson Reuters' consensus estimate of ($1.00). The medical research company earned $0.67 million during the quarter, compared to analyst estimates of $0.77 million.
View Organovo's earnings history.

Organovo's stock was trading at $5.20 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ONVO shares have increased by 145.8% and is now trading at $12.78.
View which stocks have been most impacted by COVID-19.

Shares of Organovo reverse split on the morning of Wednesday, August 19th 2020. The 1-20 reverse split was announced on Monday, August 17th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, August 18th 2020. An investor that had 100 shares of Organovo stock prior to the reverse split would have 5 shares after the split.

3 employees have rated Organovo CEO Taylor Crouch on Glassdoor.com. Taylor Crouch has an approval rating of 38% among Organovo's employees. This puts Taylor Crouch in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Organovo include Aptose Biosciences (APTO), Innate Pharma (IPHYF), Innate Pharma (IPHA), Cardiff Oncology (CRDF), Lineage Cell Therapeutics (LCTX), Surface Oncology (SURF), Autolus Therapeutics (AUTL), Eiger BioPharmaceuticals (EIGR), CASI Pharmaceuticals (CASI), Checkmate Pharmaceuticals (CMPI), PDL BioPharma (PDLI), Cabaletta Bio (CABA), LogicBio Therapeutics (LOGC), Voyager Therapeutics (VYGR) and Gamida Cell (GMDA).
View all of ONVO's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Organovo investors own include Brainstorm Cell Therapeutics (BCLI), NVIDIA (NVDA), Aerojet Rocketdyne (AJRD), The Blackstone Group (BX), LADENBURG THALM/SH SH (LTS), Advanced Micro Devices (AMD), Exelixis (EXEL), Micron Technology (MU), Novavax (NVAX) and OPKO Health (OPK).

Organovo trades on the NASDAQ under the ticker symbol "ONVO."

Organovo's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (5.36%), Jane Street Group LLC (0.23%) and Northern Trust Corp (0.22%).
View institutional ownership trends for Organovo.

ONVO stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC.
View insider buying and selling activity for Organovo or view top insider-selling stocks.

ONVO stock was purchased by a variety of institutional investors in the last quarter, including Jane Street Group LLC, and Northern Trust Corp.
View insider buying and selling activity for Organovo or or view top insider-buying stocks.

Shares of ONVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ONVO stock can currently be purchased for approximately $12.78.

Organovo has a market capitalization of $90.96 million and generates $2.20 million in revenue each year.

Organovo employs 7 workers across the globe.

The official website for Organovo is www.organovo.com.

Organovo is headquartered at 440 STEVENS AVENUE SUITE 200, SOLANA BEACH CA, 92075.

Organovo's mailing address is 440 STEVENS AVENUE SUITE 200, SOLANA BEACH CA, 92075. The medical research company can be reached via phone at 858-224-1000 or via email at [email protected]